H2N2V1, Ncbi, Merge, bibRecord, 000F12

Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.

Identifieur interne : 000F12 ( Ncbi/Merge ); précédent : 000F11; suivant : 000F13

Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.

Auteurs : Liudmila M. Tsybalova [Russie] ; Liudmila A. Stepanova [Russie] ; Marina A. Shuklina [Russie] ; Eugenia S. Mardanova [Russie] ; Roman Y. Kotlyarov [Russie] ; Marina V. Potapchuk [Russie] ; Sergei A. Petrov [Russie] ; Elena A. Blokhina [Russie] ; Nikolai V. Ravin [Russie]

Source :

PloS one [ 1932-6203 ] ; 2018.

RBID : pubmed:30138320

Descripteurs français

English descriptors

KwdEn :
- Animals, Epitopes (immunology), Epitopes (pharmacology), Female, Hemagglutinin Glycoproteins, Influenza Virus (immunology), Hemagglutinin Glycoproteins, Influenza Virus (pharmacology), Influenza A virus (immunology), Influenza Vaccines (immunology), Influenza Vaccines (pharmacology), Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Peptides (immunology), Peptides (pharmacology).
MESH :
- chemical , immunology : Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Peptides.
- chemical , pharmacology : Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Peptides.
- immunology : Influenza A virus, Orthomyxoviridae Infections.
- prevention & control : Orthomyxoviridae Infections.
- Animals, Female, Mice, Mice, Inbred BALB C.

Abstract

Influenza infection could be more effectively controlled if a multi-purpose vaccine with the ability to induce responses against most, or all, influenza A subtypes could be generated. Conserved viral proteins are a promising basis for the creation of a broadly protective vaccine. In the present study, the immunogenicity and protective properties of three recombinant proteins (vaccine candidates), comprising conserved viral proteins fused with bacterial flagellin, were compared.

DOI: 10.1371/journal.pone.0201429
PubMed: 30138320

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000016
to stream PubMed, to step Curation: 000016
to stream PubMed, to step Checkpoint: 000022

Links to Exploration step

pubmed:30138320

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.</title>
<author><name sortKey="Tsybalova, Liudmila M" sort="Tsybalova, Liudmila M" uniqKey="Tsybalova L" first="Liudmila M" last="Tsybalova">Liudmila M. Tsybalova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stepanova, Liudmila A" sort="Stepanova, Liudmila A" uniqKey="Stepanova L" first="Liudmila A" last="Stepanova">Liudmila A. Stepanova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shuklina, Marina A" sort="Shuklina, Marina A" uniqKey="Shuklina M" first="Marina A" last="Shuklina">Marina A. Shuklina</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mardanova, Eugenia S" sort="Mardanova, Eugenia S" uniqKey="Mardanova E" first="Eugenia S" last="Mardanova">Eugenia S. Mardanova</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kotlyarov, Roman Y" sort="Kotlyarov, Roman Y" uniqKey="Kotlyarov R" first="Roman Y" last="Kotlyarov">Roman Y. Kotlyarov</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Potapchuk, Marina V" sort="Potapchuk, Marina V" uniqKey="Potapchuk M" first="Marina V" last="Potapchuk">Marina V. Potapchuk</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Petrov, Sergei A" sort="Petrov, Sergei A" uniqKey="Petrov S" first="Sergei A" last="Petrov">Sergei A. Petrov</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blokhina, Elena A" sort="Blokhina, Elena A" uniqKey="Blokhina E" first="Elena A" last="Blokhina">Elena A. Blokhina</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ravin, Nikolai V" sort="Ravin, Nikolai V" uniqKey="Ravin N" first="Nikolai V" last="Ravin">Nikolai V. Ravin</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30138320</idno>
<idno type="pmid">30138320</idno>
<idno type="doi">10.1371/journal.pone.0201429</idno>
<idno type="wicri:Area/PubMed/Corpus">000016</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000016</idno>
<idno type="wicri:Area/PubMed/Curation">000016</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000016</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000022</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000022</idno>
<idno type="wicri:Area/Ncbi/Merge">000F12</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.</title>
<author><name sortKey="Tsybalova, Liudmila M" sort="Tsybalova, Liudmila M" uniqKey="Tsybalova L" first="Liudmila M" last="Tsybalova">Liudmila M. Tsybalova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stepanova, Liudmila A" sort="Stepanova, Liudmila A" uniqKey="Stepanova L" first="Liudmila A" last="Stepanova">Liudmila A. Stepanova</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shuklina, Marina A" sort="Shuklina, Marina A" uniqKey="Shuklina M" first="Marina A" last="Shuklina">Marina A. Shuklina</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mardanova, Eugenia S" sort="Mardanova, Eugenia S" uniqKey="Mardanova E" first="Eugenia S" last="Mardanova">Eugenia S. Mardanova</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kotlyarov, Roman Y" sort="Kotlyarov, Roman Y" uniqKey="Kotlyarov R" first="Roman Y" last="Kotlyarov">Roman Y. Kotlyarov</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Potapchuk, Marina V" sort="Potapchuk, Marina V" uniqKey="Potapchuk M" first="Marina V" last="Potapchuk">Marina V. Potapchuk</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Petrov, Sergei A" sort="Petrov, Sergei A" uniqKey="Petrov S" first="Sergei A" last="Petrov">Sergei A. Petrov</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg</wicri:regionArea>
<wicri:noRegion>St. Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blokhina, Elena A" sort="Blokhina, Elena A" uniqKey="Blokhina E" first="Elena A" last="Blokhina">Elena A. Blokhina</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ravin, Nikolai V" sort="Ravin, Nikolai V" uniqKey="Ravin N" first="Nikolai V" last="Ravin">Nikolai V. Ravin</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Epitopes (immunology)</term>
<term>Epitopes (pharmacology)</term>
<term>Female</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (pharmacology)</term>
<term>Influenza A virus (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (pharmacology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Peptides (immunology)</term>
<term>Peptides (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (pharmacologie)</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Peptides (immunologie)</term>
<term>Peptides (pharmacologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (pharmacologie)</term>
<term>Virus de la grippe A (immunologie)</term>
<term>Épitopes (immunologie)</term>
<term>Épitopes (pharmacologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Epitopes</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Infections à Orthomyxoviridae</term>
<term>Peptides</term>
<term>Vaccins antigrippaux</term>
<term>Virus de la grippe A</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Peptides</term>
<term>Vaccins antigrippaux</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Infections à Orthomyxoviridae</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza infection could be more effectively controlled if a multi-purpose vaccine with the ability to induce responses against most, or all, influenza A subtypes could be generated. Conserved viral proteins are a promising basis for the creation of a broadly protective vaccine. In the present study, the immunogenicity and protective properties of three recombinant proteins (vaccine candidates), comprising conserved viral proteins fused with bacterial flagellin, were compared.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30138320</PMID>
<DateCompleted><Year>2019</Year>
<Month>01</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>01</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>8</Issue>
<PubDate><Year>2018</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.</ArticleTitle>
<Pagination><MedlinePgn>e0201429</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0201429</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Influenza infection could be more effectively controlled if a multi-purpose vaccine with the ability to induce responses against most, or all, influenza A subtypes could be generated. Conserved viral proteins are a promising basis for the creation of a broadly protective vaccine. In the present study, the immunogenicity and protective properties of three recombinant proteins (vaccine candidates), comprising conserved viral proteins fused with bacterial flagellin, were compared.</AbstractText>
<AbstractText Label="METHODS">Balb/c mice were immunized intranasally with recombinant proteins comprising either one viral protein (the ectodomain of the M2 protein, 'M2e') or two viral proteins (M2e and the hemagglutinin second subunit 'HA2' epitope) genetically fused with flagellin. Further, two different consensus variants of HA2 were used. Therefore, three experimental positives were used in addition to the negative control (Flg-his). The mucosal, humoral, and T-cell immune responses to these constructs were evaluated.</AbstractText>
<AbstractText Label="RESULT">We have demonstrated that insertion of the HA2 consensus polypeptide (aa 76-130), derived from either the first (HA2-1) or second (HA2-2) virus phylogenetic group, into the recombinant Flg4M2e protein significantly enhanced its immunogenicity and protective properties. Intranasal administration of the vaccine candidates (Flg-HA2-2-4M2e or Flg-HA2-1-4M2e) induced considerable mucosal and systemic responses directed at both the M2e-protein and, in general, the influenza A virus. However, the immune response elicited by the Flg-HA2-1-4M2e protein was weaker than the one generated by Flg-HA2-2-4M2e. These recombinant proteins containing both viral peptides provide complete protection from lethal challenge with various influenza viruses: A/H3N2; A/H2N2; and A/H5N1.</AbstractText>
<AbstractText Label="CONCLUSION">This study demonstrates that the intranasal administration of Flg-HA2-2-4M2e recombinant protein induces a strong immune response which provides broad protection against various influenza viruses. This construct is therefore a strong candidate for development as a universal vaccine.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsybalova</LastName>
<ForeName>Liudmila M</ForeName>
<Initials>LM</Initials>
<Identifier Source="ORCID">0000-0002-1193-5907</Identifier>
<AffiliationInfo><Affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stepanova</LastName>
<ForeName>Liudmila A</ForeName>
<Initials>LA</Initials>
<Identifier Source="ORCID">0000-0002-8731-1834</Identifier>
<AffiliationInfo><Affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shuklina</LastName>
<ForeName>Marina A</ForeName>
<Initials>MA</Initials>
<Identifier Source="ORCID">0000-0002-7550-5519</Identifier>
<AffiliationInfo><Affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mardanova</LastName>
<ForeName>Eugenia S</ForeName>
<Initials>ES</Initials>
<AffiliationInfo><Affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kotlyarov</LastName>
<ForeName>Roman Y</ForeName>
<Initials>RY</Initials>
<Identifier Source="ORCID">0000-0002-4387-2592</Identifier>
<AffiliationInfo><Affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Potapchuk</LastName>
<ForeName>Marina V</ForeName>
<Initials>MV</Initials>
<AffiliationInfo><Affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Petrov</LastName>
<ForeName>Sergei A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Blokhina</LastName>
<ForeName>Elena A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo><Affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ravin</LastName>
<ForeName>Nikolai V</ForeName>
<Initials>NV</Initials>
<AffiliationInfo><Affiliation>Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>08</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C509609">M2e-HBc influenza vaccine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C483468">hemagglutinin, human influenza A virus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>02</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>07</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>1</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30138320</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0201429</ArticleId>
<ArticleId IdType="pii">PONE-D-18-05215</ArticleId>
<ArticleId IdType="pmc">PMC6107133</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Immunol. 2004 May 1;172(9):5598-605</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15100303</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Protoc. 2009;4(3):363-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19247286</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Aug 13;22(23-24):2993-3003</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15297047</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunogenetics. 2010 Jun;62(6):357-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20379710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomedicine. 2014 Feb;10(2):473-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23988715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Virol. 2013 Oct;3(5):521-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23978327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Aug 12;333(6044):850-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21798894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2010 May;120(5):1663-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20389023</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2017 Feb;16(2):123-136</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27653543</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2016 Jul 28;166(3):596-608</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27453466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Nov;86(21):11686-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22896619</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(12):e3942</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19079604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Apr 27;10(4):e0124677</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25915748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2016 Feb;126(2):605-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26731473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2017 Dec;19(12):641-647</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28903071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Jun;79(11):6644-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15890902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2017 Sep;509:82-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28622575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2004 Nov;72(11):6676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15501801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomed Res Int. 2013;2013:686549</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23984396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2010 Jan;38(Database issue):D854-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19906713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2018 Jan 24;9(1):359</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29367723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Comput Chem. 2004 Oct;25(13):1605-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Western Pac Surveill Response J. 2017 Jan 18;8(1):6-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28409054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2009 Jun;10(6):573-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19448659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mech Ageing Dev. 2008 May;129(5):271-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18367233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Immunol. 2008 May;45(9):2499-507</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18289677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2002 Jul 15;30(14):3059-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12136088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2017 Apr 4;17(1):241</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28376743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 May 28;28(24):4103-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19654062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mucosal Immunol. 2018 Jan;11(1):273-289</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28295019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Plant Sci. 2017 Feb 28;8:247</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28293244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Nov 10;24(44-46):6597-601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16814430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2015;386:399-421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25005927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2016 Sep 13;7:12780</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27619409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15409-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20713739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Jun 2;21(19-20):2616-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12744898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Nov 29;5(11):e13972</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21124769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Apr;89(7):3610-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25589655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomed Res Int. 2015;2015:901817</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25767809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2005 Oct;73(10):6763-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16177354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2012 Sep 27;489(7417):526-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22982990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Jan;97(1):24-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23036818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2008 Apr 25;283(17):11382-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18252707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2014 Mar 28;178:1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24417966</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13701-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20615991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Apr;89(7):3700-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25609808</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(11):e27953</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22140491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Jun 3;34(26):2926-2933</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27038130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Medicine (Baltimore). 2017 Mar;96(11):e6339</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28296763</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Dec 1;187(11):5510-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22058417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jun;88(11):6019-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24623430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Virol. 2012 Apr;2(2):134-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22482710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 2012;56(3):169-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23043596</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Jan 15;186(2):1022-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21169548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2005 Nov;73(11):7525-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16239555</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2011 Jan 17;208(1):181-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21220454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Mar;83(6):2553-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19109379</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Mar 23;10(3):e0119520</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25799221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomedicine (Lond). 2014 Feb;9(2):237-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23829488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Biotechnol. 2015 Aug 19;15:79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26286143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jan;88(1):325-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24155388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Sep 8;12(9):e0184732</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28886201</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18979-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20956293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jan 10;26(2):201-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18063235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Apr;12(4):569-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16704803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2010 Feb 26;6(2):e1000796</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20195520</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Russie</li>
</country>
<region><li>District fédéral central</li>
</region>
<settlement><li>Moscou</li>
</settlement>
</list>
<tree><country name="Russie"><noRegion><name sortKey="Tsybalova, Liudmila M" sort="Tsybalova, Liudmila M" uniqKey="Tsybalova L" first="Liudmila M" last="Tsybalova">Liudmila M. Tsybalova</name>
</noRegion>
<name sortKey="Blokhina, Elena A" sort="Blokhina, Elena A" uniqKey="Blokhina E" first="Elena A" last="Blokhina">Elena A. Blokhina</name>
<name sortKey="Kotlyarov, Roman Y" sort="Kotlyarov, Roman Y" uniqKey="Kotlyarov R" first="Roman Y" last="Kotlyarov">Roman Y. Kotlyarov</name>
<name sortKey="Mardanova, Eugenia S" sort="Mardanova, Eugenia S" uniqKey="Mardanova E" first="Eugenia S" last="Mardanova">Eugenia S. Mardanova</name>
<name sortKey="Petrov, Sergei A" sort="Petrov, Sergei A" uniqKey="Petrov S" first="Sergei A" last="Petrov">Sergei A. Petrov</name>
<name sortKey="Potapchuk, Marina V" sort="Potapchuk, Marina V" uniqKey="Potapchuk M" first="Marina V" last="Potapchuk">Marina V. Potapchuk</name>
<name sortKey="Ravin, Nikolai V" sort="Ravin, Nikolai V" uniqKey="Ravin N" first="Nikolai V" last="Ravin">Nikolai V. Ravin</name>
<name sortKey="Shuklina, Marina A" sort="Shuklina, Marina A" uniqKey="Shuklina M" first="Marina A" last="Shuklina">Marina A. Shuklina</name>
<name sortKey="Stepanova, Liudmila A" sort="Stepanova, Liudmila A" uniqKey="Stepanova L" first="Liudmila A" last="Stepanova">Liudmila A. Stepanova</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F12 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000F12 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:30138320
   |texte=   Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:30138320" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.

Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki